Press Releases

Washington, D.C. (December 19, 2019) – The Biotechnology Innovation Organization (BIO) today released the following statement in response to EPA finalizing rules on renewable volume obligations for 2020 and SRE reallocation: “Unfortunately, this…

Washington, DC (December 18, 2019) – Following the release of the Trump administration’s drug importation proposal, BIO’s President and CEO Jim Greenwood issued the following statement: “Patients deserve access to the medicines they need with…

Washington, D.C. (December 17, 2019) – A rider to the FY2020 Agriculture Appropriations Bill will direct the bioengineered AquAdvantage salmon to carry additional labeling to distinguish it from conventionally raised Atlantic salmon. This could be…

Former Congressman Jim Greenwood, President and CEO of the Biotechnology Innovation Organization (BIO), issued the following statement after the U.S. Senate confirmed Dr. Stephen Hahn to serve as the next commissioner of the Food and Drug…

Exclusion of biologics provisions in revised USMCA sets dangerous precedent for future trade talks, including with China Puts American jobs, intellectual property and leadership in medical innovation at risk WASHINGTON – BIO President and CEO Jim…

More than 135 Emerging Biotech Leaders Urge Congress to Reject H.R. 3  “Our continued success depends on maintaining an environment that supports investment in tomorrow’s discoveries.” Washington, DC: December 5, 2019 – In a letter addressed…

Washington, D.C. (November 21, 2019) – Today, the Biotechnology Innovation Organization and the Low Carbon Fuels Coalition (LCFC) announced a new joint initiative to drive adoption of low carbon fuel policies in states. Both groups will work…

Washington, D.C. (November 21, 2019) — Speaker Nancy Pelosi’s Lower Drug Costs Now Act of 2019, H.R.3, could result in at least 56 fewer new medicines for patients over 10 years, according to a new analysis from economic…

“What has set the U.S. biotech sector apart has been thoughtful, bipartisan public policy approaches that create a favorable climate in which to undertake the lengthy and risky job of investing in and developing the next biotech breakthroughs.”